Clorox (NYSE:CLX)‘s stock had its “neutral” rating restated by Bank of America in a research report issued on Thursday. They presently have a $170.00 target price on the stock, up from their previous target price of $150.00. Bank of America’s price objective suggests a potential upside of 4.89% from the company’s previous close.

Several other research firms also recently commented on CLX. Deutsche Bank downgraded shares of Clorox from a “hold” rating to a “sell” rating and set a $123.00 price target on the stock. in a research note on Wednesday, October 10th. Barclays set a $131.00 price target on shares of Clorox and gave the company a “hold” rating in a research note on Saturday, October 6th. Zacks Investment Research upgraded shares of Clorox from a “sell” rating to a “hold” rating in a research note on Monday, November 19th. Wells Fargo & Co restated a “hold” rating on shares of Clorox in a research note on Wednesday, October 31st. Finally, Citigroup upped their price target on shares of Clorox from $153.00 to $169.00 and gave the company a “hold” rating in a research note on Tuesday, November 20th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $144.93.

Shares of CLX traded down $1.56 during trading hours on Thursday, hitting $162.07. The company had a trading volume of 177,756 shares, compared to its average volume of 899,645. The firm has a market capitalization of $20.89 billion, a PE ratio of 25.89, a PEG ratio of 4.02 and a beta of 0.30. Clorox has a 12 month low of $113.57 and a 12 month high of $167.70. The company has a debt-to-equity ratio of 3.38, a current ratio of 1.07 and a quick ratio of 0.65.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Wednesday, October 31st. The company reported $1.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.59 by $0.03. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. Clorox had a net margin of 13.59% and a return on equity of 102.65%. The company’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 earnings per share. Analysts predict that Clorox will post 6.31 earnings per share for the current fiscal year.

In other Clorox news, SVP Matthew T. Laszlo sold 13,485 shares of the stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $161.04, for a total transaction of $2,171,624.40. Following the sale, the senior vice president now directly owns 20,098 shares in the company, valued at $3,236,581.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael R. Costello sold 6,882 shares of the stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $160.08, for a total transaction of $1,101,670.56. The disclosure for this sale can be found here. Insiders have sold 87,452 shares of company stock worth $13,839,402 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Parnassus Investments CA boosted its stake in shares of Clorox by 1.6% in the 2nd quarter. Parnassus Investments CA now owns 4,711,970 shares of the company’s stock valued at $637,294,000 after purchasing an additional 76,149 shares in the last quarter. Morgan Stanley boosted its stake in shares of Clorox by 178.2% in the 3rd quarter. Morgan Stanley now owns 3,063,813 shares of the company’s stock valued at $460,828,000 after purchasing an additional 1,962,433 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of Clorox by 437,400.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,750,000 shares of the company’s stock valued at $236,688,000 after purchasing an additional 1,749,600 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Clorox by 15.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,664,803 shares of the company’s stock valued at $250,403,000 after purchasing an additional 218,364 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in shares of Clorox by 57.0% in the 2nd quarter. Schroder Investment Management Group now owns 1,506,358 shares of the company’s stock valued at $201,641,000 after purchasing an additional 547,070 shares in the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: Correction

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.